Back
 AJAC  Vol.3 No.8 , August 2012
Simultaneous Determination of Atorvastatin and Glimepiride by LC-MS/MS in Human Plasma and Its Application to a Pharmacokinetic Study
Abstract: The aim of the proposed research work was to develop and validate a simple, selective high sensitive and high-throughput assay for the simultaneous estimation of Atorvastatin and Glimepiride in human plasma using liquid chromatography tandem mass spectrometry (LC-MS/MS). Atorvastatin–Glimepiride combines a competitive inhibitor of HMG-CoA reductase and a sulfonylurea anti-diabetic drug. The purpose of this study was to develop single method for Atorvastatin and Glimepiride in plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS) that would result into a simultaneous estimation of Atorvastatin and Glimepiride avoiding acid –lactone inter conversions right from sample collections to analysis on the LC-MS/MS. Sample collection procedure optimized for Atorvastatin holds good for Glimepiride, hence resulting into a simultaneous estimation of Atorvastatin and Glimepiride. Liquid-liquid extraction and liquid chromatography coupled to positive ion mode tandem mass spectrometry was used to develop the method and was validated according to US FDA guidelines. The calibration curves for two analytes were linear (R2 ≥ 0.9950, n = 4) over the concentration range of 0.2 - 30 ng/mL for Atorvastatin and 1 - 250 ng/mL for Glimepiride. Mean extraction recoveries 80.34 ± 9.43 for Atorvastatin and 88.19 ± 7.13 for Glimepiride. Intra- and inter-run mean percent accuracy was between 85% - 115% and percent imprecision was ≤15%. Stability studies revealed that Atorvastatin and Glimepiride were stable in plasma during bench top (10.5 h at room temperature), in Injector (47.5 h), at the end of three successive freeze and thaw cycles and long term at -65℃ ± 15℃ for 114 days. The method was successfully applied to the study of pharmacokinetics of Atorvastatin and Glimepiride in healthy volunteers. Simultaneous estimation of Atorvastatin and Glimepiride is cost effective, reduces analysis cycle time, enables effective utilization of resources and reduces bleeding burden on human volunteers.
Cite this paper: K. Hotha, N. Yarramu, T. Kandibedala, V. Dasari and V. Vobalaboina, "Simultaneous Determination of Atorvastatin and Glimepiride by LC-MS/MS in Human Plasma and Its Application to a Pharmacokinetic Study," American Journal of Analytical Chemistry, Vol. 3 No. 8, 2012, pp. 559-569. doi: 10.4236/ajac.2012.38074.
References

[1]   H. Lennern?s, “Clinical Pharmacokinetics of Atorvastatin,” Clinical Pharmacokinetics, Vol. 42, No. 13, 2003, pp. 1141-1160. doi:10.2165/00003088-200342130-00005

[2]   R. L. Lins, K. E. Matthys, et al., “Pharmacokinetics of Atorvastatin and Its Metabolites After Single and Multi- ple Dosing in Hypercholesterolaemic Haemodialysis Patients,” Nephrology Dialysis Transplantation, Vol. 18, No. 5, 2003, pp. 967-976. doi:10.1093/ndt/gfg048

[3]   S. N. Davis, “The Role of Glimepiride in the Effective Management of Type 2 Diabetes,” Journal of Diabetes and its Complications, Vol. 18, No. 6, 2004, pp. 367-376. doi:10.1016/j.jdiacomp.2004.07.001

[4]   V. J. Galani and M. Vyas, “In Vivo and in Vitro Drug Interactions Study of Glimepiride with Atorvastatin and Rosuvastatin,” Journal of Young Pharmacists, Vol. 2, No. 2, 2010, pp. 196-200. doi:10.4103/0975-1483.63169

[5]   D. Liu, J. Jiang, H. Zhou and P. Hu, “Quantitative Determination of Atorvastatin and Para-Hydroxy Atorvastatin in Human Plasma by LC-MS-MS,” Journal of Chromatographic Science, Vol. 46, No. 10, 2008, pp. 862-866.

[6]   M. A. Khan, S. Sinha, S. Vartak, A. Bhartiya and S. Kumar, “LC Determination of Glimepiride and Its Related Impurities,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 39, No. 4, 2005, pp. 928-943. doi:10.1016/j.jpba.2005.06.007

[7]   A. Karthik, G. Subrama-nian, C. Mallikarjuna Rao, K. Bhat, A. R. Kumar, P. Musmade, M. Surulivelrajan, K. Karthikeyan and N. Udupa, “Simultaneous Determination of Pioglitazone and Glimepiride in Bulk Drug and Pharmaceutical Dosage form by RP-HPLC Method,” Pakistan Journal of Pharmaceutical Sciences, Vol. 21, No. 4, 2008, pp. 421-425.

[8]   B. X. He, L. Shi, J. Qiu, X. H. Zeng, L. Tao, R. Li, C. J. Hong, X. L. Gu, F. Y. Dong, L. Yang and S. J. Zhao, “Quantitative Determination of Atorvastatin and Ortho-Hydroxy Atorvastatin in Human Plasma by Liquid Chro- matography Tandem Mass Spectrometry and Pharmacokinetic Evaluation,” Methods and Findings Experimental and Clinical Pharmacology, Vol. 32, No. 7, 2010, pp. 481-487. doi:10.1358/mf.2010.32.7.1487086

[9]   R. V. S. Nirogi, V. N. Kandikere, et al., “Simultaneous Quantification of Atorvastatin and Active Metabolites in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry Using Rosuvastatin as Internal Standard,” Biomedical Chromatography, Vol. 20, No. 9, 2006, pp. 924-936. doi:10.1002/bmc.622

[10]   Md. K. Pasha, S. Muzeeb, S. J. S. Basha, D. Shashikumar, R. Mullangi and N. R. Srinivas, “Analysis of Five HMG-CoA Reductase Inhibi-tors—Atorvastatin, Lovastatin, Pravastatin, Rosuvastatin and Simvastatin: Pharmacological, Pharmacokinetic and Analytical Overview and Development of a New Method for Use in Pharmaceutical Formulations Analysis and in Vitro Metabolism Studies,” Biomedical Chromatography, Vol. 20, No. 3, 2006, pp. 282-293. doi:10.1002/bmc.561

[11]   N. R. Pilli, J. K. Inamadugu, R. Mullangi, V. K. Karra, J. R. Vaidya and J. V. Rao, “Simultaneous Determination of Atorvastatin, Amlodipine, Ramipril and Benazepril in Human Plasma by LC-MS/MS and Its Application to a Human Pharmacokinetic Study,” Biomedical Chromatography, Vol. 25, No. 4, 2011, pp. 439-449. doi:10.1002/bmc.1462

[12]   J. S. Macwan, I. A. Ionita, M. Dostalek and F. Akhlaghi, “Development and Validation of a Sensitive, Simple, and Rapid Method for Simultaneous Quantitation of Atorvastatin and Its Acid and Lactone. Metabolites by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/ MS),” Analytical and Bioanalytical Chemistry, Vol. 400, No. 2, 2011, pp. 423-433. doi:10.1007/s00216-011-4804-y

[13]   R. Bonfilio, M. B. de Araújo and H. R. N. Salgado, “Review of Analytical Techniques for Determination of Gli- mepiride: Present and Perspectives,” Therapeutic Drug Monitoring, Vol. 32, No. 5, 2010, pp. 550-559. doi:10.1097/FTD.0b013e3181eea55a

[14]   H. Kim, K. Y. Chang, C. H. Park and M. S. Jang, “Determination of Glimepiride in Human Plasma by LC-MS- MS and Comparison of Sample Preparation Methods for Glimepiride,” Chromatographia, Vol. 60, No. 1, 2004, pp. 93-98. doi:10.1365/s10337-004-0351-4

[15]   N. Yüzüak, T. ?zden, S. Eren and S. ?zilhan, “Determination of Glimepiride in Human Plasma by LC-MS-MS,” Chromatographia, Vol. 66, No. 1, 2007, pp. 165-168.

[16]   S. Samala, S. R. Tatipamula and C. Veeresham, “Determination of Glimepiride in Rat Serum by Rp-Hplc Method,” American Journal of Analytical Chemistry, Vol. 2, No. 2, 2011, pp. 152-157. doi:10.4236/ajac.2011.22017

[17]   Y. Dotsikas, C. Kousoulos, G. Tsatsou and Y. L. Loukas, “Development of a Rapid Method for the Determination of Glimepiride in Human Plasma Using Liquid-Liquid Extraction Based on 96-Well Format Micro-Tubes and Liquid Chromatography/Tandem Mass Spectrometry,” Rapid Communications in Mass Spectrometry, Vol. 19, No. 1, 2005, pp. 2055-2061. doi:10.1002/rcm.2028

[18]   P. Sengupta, U. Bhaumik, A. Ghosh, A. K. Sarkar, B. Chatterjee, A. Bose and T. K. Pal, “LC-MS-MS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study,” Chromatographia, Vol. 69, No. 1, 2009, pp. 1243-1250. doi:10.1365/s10337-009-1056-5

[19]   L. Chakradhar, R. Kallem, A. Karthik, B. T. Sundari, S. Ramesh, R. Mullangi and N. R. Srinivas, “Rapid and Highly Sensitive Method for the Determination of Glimepiride in Human Plasma by Liquid Chromatography- Electrospray Ionization Tandem Mass Spectrometry: Application to a Pre-Clinical Pharmacokinetic Study,” Biomedical Chromatography, Vol. 22, No. 1, 2008, pp. 58- 63. doi:10.1002/bmc.896

[20]   I. I. Salem, J. Idrees and J. I Tamimi, “Determination of Glimepiride in Human Plasma by Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry,” Journal of Chromatography B, Vol. 799, No. 1, 2004, pp. 103-109. doi:10.1016/j.jchromb.2003.10.024

[21]   J. Deepti, J. Surendra, J. Deepak and A. Maulik, “Simultaneous Estimation of Metformin Hydrochloride, Pioglitazone Hydro-chloride, and Glimepiride by RP-HPLC in Tablet Formulation,” Journal of Chroamtographi Science, Vol. 46, No. 6, 2008, pp. 501-504.

[22]   S. R. Dhaneshwar, J. V. Salunkhe and V. K. Bhusari, “Validated HPTLC Method for Simultaneous Estimation of Metformin Hydrochloride, Atorvastatin and Glimepiride in Bulk Drug and Formulation,” Journal of Analytical and Bioanalytical Techniques, Vol. 109, No. 1, 2010, pp. 1-5. doi:10.4172/2155-9872.1000109

[23]   H. Kotagiri, R. Gannu, C. R. Palem, S. K. Yamsani, V. V. Yamsani and M. R. Yamsani, “Simultaneous Determination of Glimepiride and Atorvastatin in Human Serum by High Performance Liquid Chromatography: Application to Pharmacokinetic Study,” Journal of Liquid Chromatography and Related Technologies, Vol. 34, No. 19, 2011, pp. 2420-2432. doi:10.1080/10826076.2011.591023

[24]   US Food and Drug Administration, “Guidance for Industry: Bioanalytical Method Validation,” US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, 2001.

[25]   US Food and Drug Administration, “Guidance for Industry: Safety Testing of Drug Metabolites,” US Department of Health and Human Services, US FDA, Center for Drug Evaluation and Research, 2008.

[26]   C. T. Viswanathan, S. Bansal and B. Booth, “Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays. Workshop/Conference Report,” The AAPS Journal, Vol. 9, No. 1, 2007, pp. E30-E42. doi:10.1208/aapsj0901004

[27]   D. M. Fast, M. Kelley and C. T. Viswanathan, “AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Sam-ples—Implications of Crystal City Recommendations Workshop Report and Follow-Up,” The AAPS Journal, Vol. 11, No. 2, 2009, pp. 238-241. doi:10.1208/s12248-009-9100-9

[28]   G. Liu, Q. C. Ji and M. E. Arnold, “Identifying, Evaluating and Controlling Bioanalytical Risks Resulting from Non Uniform Matrix Ion Suppression/Enhancement and Nonlinear Liquid Chromatography-Mass Spectrometry Assay Response,” Ana-lytical Chemistry, Vol. 82, No. 23, 2010, pp. 9671-9677. doi:10.1021/ac1013018

[29]   E. Chambers, D. M. Wagrowski-Diehl, Z. Lu and J. R. Mazzeoe, “Systematic and Comprehensive Strategies for Reducing Matrix Effects in LC-MS/MS Analyses,” Journal of Chromatography B, Analytical Technologies in the Biomedical Life Sciences, Vol. 852, No. 1, 2007, pp. 22-34. doi:10.1016/j.jchromb.2006.12.030

[30]   Y. Xia, M. Jemal, “Phospholipids in Liquid Chromatography-Mass Spectrometry Bioanalysis: Comparison of Three Tandem Mass Spectrometric Techniques for Monitoring Plasma Phospholipids, the Effect of Mobile-Phase Composition on Phospholipids Elution and the Association of Phospholipids with Matrix Effects,” Rapid Communication in Mass spectrometry, Vol. 23, No. 14, 2009, pp. 2125-2138.

[31]   J. L. Little, M. F. Wempe and C. M. Buchanan , “Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Method Development for Drug Metabolism Studies: Examining Lipid Matrix Ionization Effects in Plasma,” Journal of Chromatography B, Analytical Technologies in the Biomedical life Sciences, Vol. 833, No. 2006, pp. 219-230. doi:10.1016/j.jchromb.2006.02.011

[32]   C. C?té, A. Bergeron, J. N. Mess, M. Furtado and F. Garofolo, “Matrix Effect Elimination during LC-MS/MS Bioanalytical Method Development,” Bioanalysis, Vol. 1, No. 7, 2009, pp. 1243-1257.

[33]   L. Nováková, , D. ?atínsky and P. Solich, “HPLC Methods for the Determination of Simvastatin and Atorvastatin,” Trends in Analytical Chemistry, Vol. 27, No. 4, 2008, pp. 352-367. doi:10.1016/j.trac.2008.01.013

[34]   M. Jemal and Y. Q. Xia, “Bioanalytical Method Validation Design for the Simultaneous Quantitation of Analytes That May Undergo Interconversion during Analysis,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 22, No. 5, 2000, pp. 813-827. doi:10.1016/S0731-7085(00)00245-4

[35]   M. Jemal, Z. Ouyang, B. Chen and D. Teitz, “Quantitation of the Acid and Lactone Forms of Atorvastatin and Its Biotransformation Products in Human Serum by High-Performance Liquid Chromatography with Electrospray Tandem Mass Spectrometry,” Rapid Communications in Mass Spectrometry, Vol. 13, No. 11, 1999, pp. 1003-1015. doi:10.1002/(SICI)1097-0231(19990615)13:11<1003::AID-RCM597>3.0.CO;2-L

[36]   M. J. Morris, J. D. Gilbert, J. Y. Hsieh, B. K. Mat- uszewski, H. G. Ramjit and W. F. D. Bayne, “Determination of the HMG-CoA Reductase Inhibitors Simvastatin, Lovastatin, and Pravastatin in Plasma by Gas Chromatography/Chemical Ionization Mass Spectrometry,” Biological Mass Spectrometry, Vol. 22, No. 1, 1993, pp. 1-8. doi:10.1002/bms.1200220102

[37]   W. Jacobsen, B. Kuhn, A. Soldner, G. Kirchner, K.-F. Sewing, P. A. Kollman, L. Z. Benet and U. Christians, “Lactonization Is The Critical First Step In The Disposition of the 3-Hydroxy-3-Methylglutaryl-Coa Reductase Inhibitor Atorvastatin,” Drug Metabolism and Dis-position, Vol. 28, No. 11, 2000, pp. 1369-1378.

[38]   L. R. Lins, E. Katelijne, A. Matthys, G. Verpooten, C. P. Peeters, M Dratwa, J.-C. Stolear and H. Norbert, “Pharmacokinetics of Atorvastatin and Its Metabolites after Single and Multiple Dosing in Hypercholesterolaemic Haemodialysis Patient,” Nephrology Dialysis Transplantation, Vol. 18, No. 5, 2003, pp. 967-976. doi:10.1093/ndt/gfg048

[39]   K. Gandelman, B. Malhotra, R. Robert, L. Crownover and T. Bergstrom, “Analytes of Interest and Choice of Dose: Two Important Considerations in the Design of Bioequivalence Studies with Atorvastatin,” Bioequiva-lence & Bioavailability, Vol. 3, No. 4, 2011, pp. 062-068.

[40]   T. Ahmed, S. Kollipara, A. Gautam, R. Gigras, M. Kothari, N. Saha, V. Batra and J. Paliwal, “Bioavailability and Interaction Potential of Atorvastatin and Losartan on Co-administration in Healthy Human Subjects,” Jour- nal of Bioequivalence & Bioavailability, Vol. 1, No. 1, 2009, pp. 018-027.

[41]   Anonym, “AMARYL? (Glimepiride Tablets) 1, 2, and 4 mg,” 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020496s021lbl.pdf

[42]   Anonym, “Product Monograph-Pr AMARYL? Glime-piride Tablets 1, 2 and 4 mg,” Manufacturer’s Standard, 2009. http://products.sanofi.ca/en/amaryl.pdf

[43]   Anonym, “Product Monograph-PRLIPITOR? (Atorvastatin Calcium Tablets) 10 mg, 20 mg, 40 mg and 80 mg Atorvastatin Lipid Metabolism Regulator,” 2011.

 
 
Top